Clinical Trials Directory

Trials / Sponsors / Aragon Pharmaceuticals, Inc.

Aragon Pharmaceuticals, Inc.

Industry · 16 registered clinical trials.

StatusTrialPhaseStarted
Active Not RecruitingA Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrom
Prostatic Neoplasms, Castration-Resistant
Phase 12016-02-12
CompletedA JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
Castration-Resistant Prostate Cancer
Phase 12015-12-18
Active Not RecruitingA Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participa
Prostate Cancer
Phase 32015-11-27
Active Not RecruitingAn Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Pri
Prostatic Neoplasms
Phase 32015-11-19
CompletedA Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairm
Hepatic Impairment
Phase 12015-08-13
Active Not RecruitingAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednis
Prostatic Neoplasms
Phase 32014-11-26
CompletedStudy to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927
Healthy
Phase 12014-09-01
Active Not RecruitingA Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Phase 12014-07-09
CompletedBioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male
Healthy
Phase 12014-06-01
CompletedA Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to t
Healthy
Phase 12013-12-01
Active Not RecruitingA Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms
Phase 32013-10-14
CompletedThe Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormon
Prostate Cancer
Phase 22013-03-04
Completed14C-ARN-509 Microtracer Label AME and Absolute BA Study
Healthy
Phase 12013-03-01
CompletedSafety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in C
Prostate Cancer
Phase 12013-02-05
CompletedSafety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate C
Prostate Cancer
Phase 1 / Phase 22010-07-26
No Longer AvailableAn Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant
Prostatic Neoplasms
——